BioCentury
ARTICLE | Clinical News

PRT-201: Phase III started

August 11, 2014 7:00 AM UTC

Proteon began a double-blind, placebo-controlled, U.S. Phase III trial to evaluate a single dose of 30 Ug PRT-201 in 300 CKD patients undergoing surgical placement of an AVF. PRT-201 has Orphan Drug a...